Pathology Doctors in Jacksonville, IL Accepting Medicare

2 Pathology doctors found. Showing 1 - 2

Dr. Mark Stephan Dolz, DO Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 1600 W Walnut, Passavant Area Hospital - Laboratory, Jacksonville, IL 62650 Phone: 217-245-9541    Fax: 217-479-5648

Dr. James William Veenstra, M.D. Pathology - Hematology Medicare: Not Enrolled in Medicare Practice Location: 1383 Mcglasson Rd, Jacksonville, IL 62650 Phone: 217-472-5500

News Archive

Canadian cancer patients cross the border for second opinion

Two years ago, Beverlee London of Toronto was diagnosed with Stage I lung cancer. London was given the news by her lung specialist in Toronto that she had a malignant tumor on her right lung. She also decided at the time to visit the Barbara Ann Karmanos Cancer Center in Detroit for a second opinion, since she had family living in the area.

FDA panel votes against novel diabetes drug citing adverse effects

An advisory panel for the US Food and Drugs Administration voted 9-6 that the FDA should not yet approve dapagliflozin, a new type of diabetes drug that makes the body dump sugar and lose weight. Signals of possible liver damage and of breast and bladder cancer worried the experts.

Recent studies show higher scores of Yale Food Addiction Scale in binge eating disorder

Clinical food addiction diagnoses are nowadays measure by a tool called Yale Food Addiction Scale which was initially developed on the basis of criteria for identifying substance addictions.

MIT scientists model structure of alpha synuclein protein associated with Parkinson's

Clumps of proteins that accumulate in brain cells are a hallmark of neurological diseases such as dementia, Parkinson's disease and Alzheimer's disease. Over the past several years, there has been much controversy over the structure of one of those proteins, known as alpha synuclein.

Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.

Read more Medical News

› Verified 2 days ago